Lisata Therapeutics (LSTA)
NASDAQ:LSTA
Want to see LSTA full AI Analyst Report?
Top Page
Lisata Therapeutics
(NASDAQ:LSTA)
Select Model
Select Model
Rating:47Neutral
Price Target:
$3.00
▲(53.85% Upside)
Action:Reiterated
Date:05/14/26
The score is primarily held down by very weak financial performance (minimal revenue, large ongoing losses, and persistent negative free cash flow despite no debt). Technicals also lean soft (negative MACD and low RSI, with price below key medium-term averages). Corporate events provide partial support via the announced acquisition terms, but extensions and uncertainty around tender-offer timing limit the uplift, and valuation is constrained by loss-making earnings and no dividend yield.
Positive Factors
Zero debt / low leverage
Having no reported debt materially reduces solvency and interest-cost risk for a clinical-stage biotech. Over the next several months this preserves optionality for dilution, M&A, or strategic funding and lowers bankruptcy risk relative to peers with leverage.
Negative Factors
Persistent negative cash flow
Sustained negative operating and free cash flow reflects ongoing cash burn from clinical and R&D activities. Without product revenues, this creates durable financing dependence that can force dilution, constrain R&D pacing, or necessitate asset-sale or transaction-driven outcomes within months.
Read all positive and negative factors
Positive Factors
Negative Factors
Zero debt / low leverage
Having no reported debt materially reduces solvency and interest-cost risk for a clinical-stage biotech. Over the next several months this preserves optionality for dilution, M&A, or strategic funding and lowers bankruptcy risk relative to peers with leverage.
Read all positive factors
Lisata Therapeutics (LSTA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$28.41M
Dividend YieldN/A
Average Volume (3M)34.52K
Price to Earnings (P/E)―
Beta (1Y)0.18
Revenue Growth-83.00%
EPS Growth19.02%
CountryUS
Employees26
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.86
Shares Outstanding9,106,391
10 Day Avg. Volume57,561
30 Day Avg. Volume34,515
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.09
Price to Sales (P/S)95.05
P/FCF Ratio-1.01
Enterprise Value/Market Cap0.56
Enterprise Value/Revenue93.52
Enterprise Value/Gross Profit94.63
Enterprise Value/Ebitda-0.94
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.96
Revenue Forecast (FY)N/A
Lisata Therapeutics Business Overview & Revenue Model
Company Description
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a rec...
How the Company Makes Money
null...
Lisata Therapeutics Earnings Call Summary
Earnings Call Date:Nov 06, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Aug 17, 2026
Earnings Call Sentiment Neutral
Lisata Therapeutics has made significant progress in its clinical programs and strategic partnerships, reflecting strong operational management and promising trial results. However, the need for additional capital for Phase III trials poses a significant challenge. The market's lack of response to positive developments highlights ongoing investor skepticism or broader market conditions.Positive Updates
Strategic Alliance with GATC Health
Lisata entered into a strategic alliance with GATC Health to use their advanced AI technology for drug discovery, identifying several development candidates for clinical development in 2026.
Negative Updates
Need for Additional Capital
The company acknowledged the need to raise substantial funds or secure partnerships to support a Phase III trial, highlighting the significant financial challenge ahead.
Read all updates
Q3-2025 Updates
Positive
Negative
Strategic Alliance with GATC Health
Lisata entered into a strategic alliance with GATC Health to use their advanced AI technology for drug discovery, identifying several development candidates for clinical development in 2026.
Read all positive updates
Company Guidance
During the Lisata Therapeutics Third Quarter 2025 Financial Results and Business Update Conference Call, the company provided guidance on several key metrics. They reported a decrease in operating expenses to $4.4 million for the third quarter of 2025, down from $5.3 million in the same period the previous year, marking a 17.3% reduction. Research and development expenses also declined by 22.9% to $2 million. The company reported a net loss of $4.2 million, compared to $4.9 million in the third quarter of 2024. Lisata highlighted their cash and cash equivalents totaling approximately $19 million as of September 30, 2025, with projections to support operations into the first quarter of 2027. Additionally, they discussed their strategic alliance with GATC Health and a nonexclusive global license agreement with Catalent, indicating a promising period ahead with several anticipated milestones.Lisata Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
45
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 170.00K | 170.00K | 1.00M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 168.00K | 24.00K | 1.00M | 0.00 | 0.00 | 0.00 |
| EBITDA | -16.82M | -18.06M | -22.23M | -25.52M | -57.53M | -29.00M |
| Net Income | -16.35M | -16.59M | -19.98M | -20.84M | -54.23M | -27.47M |
Balance Sheet | ||||||
| Total Assets | 14.06M | 17.74M | 35.00M | 54.69M | 73.03M | 97.01M |
| Cash, Cash Equivalents and Short-Term Investments | 13.06M | 15.96M | 31.25M | 50.53M | 69.23M | 94.97M |
| Total Debt | 0.00 | 0.00 | 137.00K | 168.00K | 485.00K | 714.00K |
| Total Liabilities | 3.39M | 3.14M | 5.68M | 6.80M | 6.71M | 5.01M |
| Stockholders Equity | 10.93M | 14.86M | 29.57M | 48.15M | 66.58M | 92.25M |
Cash Flow | ||||||
| Free Cash Flow | -13.66M | -15.98M | -19.36M | -20.03M | -21.45M | -22.30M |
| Operating Cash Flow | -13.63M | -15.95M | -19.36M | -20.03M | -21.17M | -22.25M |
| Investing Cash Flow | 5.66M | 15.09M | 13.23M | 10.10M | 28.91M | -54.90M |
| Financing Cash Flow | 803.00K | 599.00K | -206.00K | 385.00K | -224.00K | 85.28M |
Lisata Therapeutics Technical Analysis
Negative
1.95
Price Trends
4.08
Negative
3.88
Negative
3.10
Positive
Market Momentum
-0.22
Negative
38.91
Neutral
32.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LSTA, the sentiment is Negative. The current price of 1.95 is below the 20-day moving average (MA) of 3.20, below the 50-day MA of 4.08, and below the 200-day MA of 3.10, indicating a neutral trend. The MACD of -0.22 indicates Negative momentum. The RSI at 38.91 is Neutral, neither overbought nor oversold. The STOCH value of 32.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LSTA.
Lisata Therapeutics Risk Analysis
Lisata Therapeutics disclosed 80 risk factors in its most recent earnings report. Lisata Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lisata Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $28.41M | -2.51 | -84.39% | ― | -83.00% | 19.02% | |
46 Neutral | $14.47M | -0.18 | -77.46% | ― | ― | 55.15% | |
45 Neutral | $5.77M | -0.17 | -389.34% | ― | ― | 99.36% | |
44 Neutral | $7.56M | -0.49 | -281.30% | ― | ― | 86.07% | |
41 Neutral | $31.72M | 1.23 | 288.40% | ― | ― | 86.10% |
* Healthcare Sector Average
LSTA
Lisata Therapeutics
3.18
0.68
27.20%
APVO
Aptevo Therapeutics
4.56
-132.25
-96.67%
CTXR
Citius Pharmaceuticals
0.58
-0.10
-14.83%
PCSA
Processa Pharmaceuticals
2.61
-3.42
-56.72%
APLM
Apollomics
13.53
6.77
100.07%
Lisata Therapeutics Corporate Events
Business Operations and StrategyM&A Transactions
Lisata Therapeutics Amends Kuva Labs Merger Agreement Timeline
Neutral
May 4, 2026
On May 3, 2026, Lisata Therapeutics, Inc. and Kuva Labs Inc., together with Kuva Acquisition Corp., amended their March 6, 2026 merger agreement to extend the deadline for commencing Kuva’s tender offer for all outstanding Lisata common shar...
Business Operations and StrategyM&A TransactionsRegulatory Filings and Compliance
Lisata Therapeutics extends deadline for Kuva tender offer
Negative
Apr 15, 2026
On April 2, 2026, Lisata Therapeutics and Kuva Labs agreed to extend the deadline for Kuva’s subsidiary to launch a tender offer to acquire all outstanding Lisata common shares, moving the date from April 3 to April 13, 2026, or another mutu...
M&A Transactions
Lisata Therapeutics Delays Tender Offer Launch in Merger
Neutral
Apr 3, 2026
On April 2, 2026, Lisata Therapeutics, Inc., Kuva Labs Inc. and Kuva Acquisition Corp. agreed to extend the deadline for Kuva’s tender offer to acquire all outstanding Lisata common shares under their March 6, 2026 merger agreement. The tend...
Business Operations and StrategyDelistings and Listing ChangesM&A Transactions
Lisata Therapeutics to Be Acquired by Kuva Labs
Positive
Mar 9, 2026
On March 6, 2026, Lisata Therapeutics agreed to be acquired by privately held Kuva Labs in an all-cash tender offer valuing its common shares at $5.00 each at closing plus one non-tradable contingent value right per share, offering a potential add...
Business Operations and StrategyM&A Transactions
Lisata Extends Kuva Labs Acquisition Term Sheet Timeline
Neutral
Feb 27, 2026
Lisata Therapeutics, Inc. and Kuva Labs Inc. had previously entered into a binding term sheet on January 20, 2026, outlining the framework for a potential negotiated acquisition of Lisata by Kuva via a tender offer for all outstanding Lisata commo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.